Edesa Biotech Inc — Quarterly Cash Flow (NASDAQ:EDSA) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Total assets 5.23 M3.81 M4.16 M16.45 M14.8 M13.53 M14.71 M Total liabilities 2.36 M1.83 M1.9 M914.7 K672.67 K1.08 M756.16 K Total equity 2.87 M1.98 M2.26 M15.54 M14.13 M12.45 M13.95 M Total liabilities & shareholders' equities 5.23 M3.81 M4.16 M16.45 M14.8 M13.53 M14.71 M Total debt ——————— Net debt ———————

Notizie

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.76%

Le azioni di Edesa Biotech salgono sui dati positivi dello studio di Fase 3

Edesa Biotech stock surges on positive Phase 3 trial data

Edesa Biotech reports mortality reduction in phase 3 trial

Edesa Biotech aumenta il limite dell’offerta at-the-market a 2,26 milioni di dollari

Edesa Biotech increases at-the-market offering limit to $2.26 million

Edesa Biotech, Inc. (EDSA) Presents at LSX Investival Showcase Europe 2025 - Slideshow (NASDAQ:EDSA) 2025-11-17

Edesa Biotech riporta risultati positivi di Fase 3 per candidato farmaco contro ARDS

Edesa’s ARDS drug shows 25% reduction in death risk in phase 3 trial

Edesa Biotech reports positive Phase 3 results for ARDS drug candidate

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Dow Jumps Over 100 Points; Deere Posts Upbeat Earnings - AppLovin (NASDAQ:APP), Dutch Bros (NYSE:BROS)